EA201990621A1 - Кристаллические формы ингибитора лизилоксидаза-подобного белка 2 и способы получения - Google Patents

Кристаллические формы ингибитора лизилоксидаза-подобного белка 2 и способы получения

Info

Publication number
EA201990621A1
EA201990621A1 EA201990621A EA201990621A EA201990621A1 EA 201990621 A1 EA201990621 A1 EA 201990621A1 EA 201990621 A EA201990621 A EA 201990621A EA 201990621 A EA201990621 A EA 201990621A EA 201990621 A1 EA201990621 A1 EA 201990621A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
inhibitor
loxl2
protein
crystallic
Prior art date
Application number
EA201990621A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид Лонерган
Кевин Росс Холм
Мартин У. Роуботтом
Original Assignee
Фармакеа, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармакеа, Инк. filed Critical Фармакеа, Инк.
Publication of EA201990621A1 publication Critical patent/EA201990621A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201990621A 2016-09-07 2017-09-06 Кристаллические формы ингибитора лизилоксидаза-подобного белка 2 и способы получения EA201990621A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662384596P 2016-09-07 2016-09-07
PCT/US2017/050332 WO2018048943A1 (en) 2016-09-07 2017-09-06 Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making

Publications (1)

Publication Number Publication Date
EA201990621A1 true EA201990621A1 (ru) 2019-09-30

Family

ID=61561660

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990621A EA201990621A1 (ru) 2016-09-07 2017-09-06 Кристаллические формы ингибитора лизилоксидаза-подобного белка 2 и способы получения

Country Status (14)

Country Link
US (2) US10774069B2 (enExample)
EP (1) EP3510023B1 (enExample)
JP (1) JP7079772B2 (enExample)
KR (1) KR102587178B1 (enExample)
CN (1) CN109983006B (enExample)
AU (1) AU2017324445A1 (enExample)
BR (1) BR112019004517A2 (enExample)
CA (1) CA3036064A1 (enExample)
EA (1) EA201990621A1 (enExample)
IL (1) IL265192A (enExample)
MA (1) MA46204A (enExample)
MX (1) MX390964B (enExample)
SG (1) SG11201901999XA (enExample)
WO (1) WO2018048943A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10766860B2 (en) * 2015-03-06 2020-09-08 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
MX376835B (es) 2015-03-06 2025-03-07 Pharmakea Inc Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
AU2017218889A1 (en) 2016-02-09 2018-08-30 Pharmakea, Inc. Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
SG11201901999XA (en) * 2016-09-07 2019-04-29 Pharmakea Inc Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
KR20230162996A (ko) 2016-09-07 2023-11-29 파마케아, 인크. 리실 옥시다제 유사 2 억제제의 용도
GB201716871D0 (en) 2017-10-13 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Compounds
CN114487139B (zh) * 2020-10-27 2025-01-14 鲁南制药集团股份有限公司 一种盐酸西替利嗪有关物质的检测方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
IE56702B1 (en) * 1982-12-01 1991-11-06 Usv Pharma Corp Antiinflammatory antiallergic compounds
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US7125880B1 (en) 1995-06-06 2006-10-24 Pfizer Inc. Corticotropin releasing factor antagonists
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
CA2397633A1 (en) 2000-01-18 2001-07-26 Pfizer Products Inc. Corticotropin releasing factor antagonists
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
FI20030030A0 (fi) 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
AU2004240649A1 (en) 2003-05-19 2004-12-02 Irm, Llc Immunosuppressant compounds and compositions
BRPI0507250A (pt) 2004-01-29 2007-06-26 Pfizer Prod Inc combinações para tratar desordens do snc
US7381750B2 (en) 2004-03-12 2008-06-03 Eli Lilly And Company Amino-phenoxymethyl-benzamide opioid receptor antagonists
US7378448B2 (en) 2004-03-15 2008-05-27 Eli Lilly And Company Diphenylether amide derivatives as opioid receptor antagonists
MXPA06012333A (es) 2004-04-30 2007-01-17 Takeda Pharmaceutical Compuesto de amida heterociclico y uso del mismo como un inhibidor mmp-13.
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
CA2580042A1 (en) 2004-09-10 2006-03-16 Pfizer Products Inc. Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives
JP2008512440A (ja) 2004-09-10 2008-04-24 ファイザー・プロダクツ・インク ジアザビシクロ化合物含有ベンゾイソオキサゾールを用いる気分障害の治療方法
EP1807417A2 (en) 2004-11-04 2007-07-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
DE102004056226A1 (de) 2004-11-22 2006-05-24 Burchardt, Elmar Reinhold, Dr.Dr. Neuartige Inhibitoren der Lysyloxidase
JP2008528628A (ja) 2005-01-31 2008-07-31 メルク エンド カムパニー インコーポレーテッド 抗糖尿病性二環式化合物
AR055041A1 (es) 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
CA2618586A1 (en) 2005-08-11 2007-02-15 Merck Frosst Canada Ltd. Novel substituted 1,2,3-triazolylmethyl-benzothiophene or -indole and their use as leukotriene biosynthesis inhibitors
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
ITMI20051943A1 (it) * 2005-10-14 2007-04-15 Procos Spa Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070219206A1 (en) 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
CA2636043A1 (en) 2006-01-23 2007-08-02 Amira Pharmaceuticals, Inc. Tricyclic inhibitors of 5-lipoxygenase
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
JP2010501553A (ja) 2006-08-18 2010-01-21 アストラゼネカ アクチボラグ Mchr1アンタゴニストとしてのチエノピリミジン−4−オン誘導体およびチエノピリダジン−7−オン誘導体
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
CA2693310C (en) 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
EP2458995A1 (en) 2009-07-28 2012-06-06 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
MX2012002271A (es) 2009-08-21 2012-07-20 Gilead Biologics Inc Metodos y composiciones terapeuticas.
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
WO2011109799A1 (en) 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
CA2818542A1 (en) * 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
IN2014MN01982A (enExample) 2012-04-25 2015-07-10 Raqualia Pharma Inc
WO2014070939A1 (en) * 2012-10-30 2014-05-08 Gilead Sciences, Inc. Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
EP2937335A4 (en) 2012-12-18 2016-09-14 Ea Pharma Co Ltd HETEROCYCLIC AMID DERIVATIVE AND MEDICAMENT THEREWITH
AU2015298491A1 (en) 2014-02-14 2016-09-01 The University Of British Columbia Modulators of caspase-6
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
CA2975196A1 (en) 2015-02-15 2016-08-18 F. Hoffmann-La Roche Ag 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists
MX376835B (es) * 2015-03-06 2025-03-07 Pharmakea Inc Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
US10766860B2 (en) 2015-03-06 2020-09-08 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
SG11201901999XA (en) 2016-09-07 2019-04-29 Pharmakea Inc Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
KR20230162996A (ko) 2016-09-07 2023-11-29 파마케아, 인크. 리실 옥시다제 유사 2 억제제의 용도

Also Published As

Publication number Publication date
US20190202805A1 (en) 2019-07-04
CN109983006A (zh) 2019-07-05
JP7079772B2 (ja) 2022-06-02
EP3510023A1 (en) 2019-07-17
JP2019532919A (ja) 2019-11-14
SG11201901999XA (en) 2019-04-29
EP3510023A4 (en) 2020-03-18
US20200361901A1 (en) 2020-11-19
WO2018048943A1 (en) 2018-03-15
MX390964B (es) 2025-03-21
CA3036064A1 (en) 2018-03-15
US11459309B2 (en) 2022-10-04
KR102587178B1 (ko) 2023-10-06
BR112019004517A2 (pt) 2019-08-13
MA46204A (fr) 2021-03-17
CN109983006B (zh) 2022-02-25
KR20190052040A (ko) 2019-05-15
AU2017324445A1 (en) 2019-04-11
IL265192A (en) 2019-05-30
MX2019002615A (es) 2019-10-15
US10774069B2 (en) 2020-09-15
EP3510023B1 (en) 2024-06-19

Similar Documents

Publication Publication Date Title
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
MX390964B (es) Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion.
MX2022004937A (es) Inhibidores de las cinasas raf.
ZA201800022B (en) Substituted heterocyclyl derivatives as cdk inhibitors
MX377837B (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas.
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
CY1125488T1 (el) Παραγωγα πυριδινης και θεραπευτικες χρησεις αυτων ως αναστολεις trpc6
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
NO20091989L (no) Forbindelser som modulerer c-fms og/eller C-kit aktivitet og deres anvendelse
EA201270480A1 (ru) Новые соединения
MX2019000536A (es) Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
ECSP077985A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
EA200971077A1 (ru) Гетероциклические модуляторы киназы
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
TN2017000158A1 (en) Carbazole derivatives
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
EA201690741A1 (ru) Составы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2